var data={"title":"Thalidomide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Thalidomide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7036?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">see &quot;Thalidomide: Drug information&quot;</a> and <a href=\"topic.htm?path=thalidomide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Thalidomide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708930\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pregnancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">If thalidomide is taken during pregnancy, it may cause severe birth defects or embryo-fetal death. Thalidomide should never be used by females who are pregnant or who could become pregnant while taking thalidomide. Even a single dose (1 capsule [regardless of strength]) taken by a pregnant woman during pregnancy may cause severe birth defects.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of this toxicity and in an effort to make the chance of embryo-fetal exposure to thalidomide as negligible as possible, thalidomide is approved for marketing only through a special restricted distribution program: Thalomid REMS program, approved by the Food and Drug Administration. Information about Thalomid and the Thalomid REMS program is available at https://www.celgeneriskmanagement.com or by calling the manufacturer's toll-free number 1-888-423-5436.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Thromboembolic events:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The use of thalidomide in multiple myeloma results in an increased risk of venous thromboembolism, such as deep venous thrombosis and pulmonary embolism. This risk increases significantly when thalidomide is used in combination with standard chemotherapeutic agents including dexamethasone. In 1 controlled trial, the rate of venous thromboembolism was 22.5% in patients receiving thalidomide in combination with dexamethasone compared with 4.9% in patients receiving dexamethasone alone (P = 0.002). Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Instruct patients to seek medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. Consider thromboprophylaxis based on an assessment of individual patients' underlying risk factors.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226481\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Thalomid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226482\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Thalomid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1038544\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Angiogenesis Inhibitor</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Immunosuppressant Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Tumor Necrosis Factor (TNF) Blocking Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1038576\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">see &quot;Thalidomide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>AIDS-related aphthous stomatitis:</b> Limited data available: Adolescents &ge;13 years: Oral: 200 mg once daily at bedtime for 4 weeks or sooner if resolution. May be increased to 200 mg twice daily if no improvement after 4 weeks. Dosing based on double-blind, placebo-controlled trial by AIDS Clinical Trials Group (n=57, age: &ge;13 years) which showed 55% healing in treatment group vs 7% in placebo (Jacobson 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic graft-versus-host disease (refractory), treatment:</b> Limited data available: Children &ge;2 years and Adolescents: Oral: Initial: 3 to 6 mg/kg/<b>day</b> (maximum initial daily dose: 100 mg/<b>day</b>) at bedtime or in 2 to 4 divided doses before meals; may be adjusted at &ge;2 week intervals based on patient response up to 12 mg/kg/<b>day</b> in 3 to 4 divided doses (maximum daily dose: 800 mg/<b>day</b>) (Browne 2000; Rovelli 1998; Wolff 2011); one trial using initial doses of 3 mg/kg/dose every 6 hours (dose adjusted to attain goal thalidomide concentration of &ge;5 mcg/mL 2 hours postdose) (Vogelsang 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Crohn's disease/ulcerative colitis (refractory), treatment:</b> Limited data available: Children &ge;1 year and Adolescents: Oral: 0.5 to 3 mg/kg/<b>day</b> (maximum daily dose: 300 mg/<b>day</b>), usually dosed once daily in the evening; titrate to lowest effective dose after remission is achieved (Facchini 2001; Lazzerini 2007; Martelossi 2004; Zheng 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Erythema nodosum leprosum (ENL), cutaneous:</b> Children &ge;12 years and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Acute: Initial: 100 to 300 mg once daily at bedtime; continue until signs/symptoms subside (usually ~2 weeks), then taper off in 50 mg decrements every 2 to 4 weeks. For severe cases with moderate to severe neuritis, corticosteroids may be initiated with thalidomide (taper off and discontinue corticosteroids when neuritis improves).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients weighing &lt;50 kg: Initiate at lower end of dosage range</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe cutaneous reaction or patients previously requiring high doses: May be initiated or increased to 400 mg/day at bedtime or in divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance (prevention/suppression, or with flares during tapering attempts): Maintain on the minimum dosage necessary to control the reaction; efforts to taper should be repeated every 3 to 6 months, in decrements of 50 mg every 2 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Systemic juvenile idiopathic arthritis (SJIA):</b> Limited data available: Children &ge;3 years and Adolescents: Oral: Initial 2 mg/kg/<b>day</b>, if necessary may increase at 2-week intervals to 3 to 5 mg/kg/<b>day</b>. Data based on a multicenter, open-labeled prospective study (n=13, age: 3 to 23 years); within 4 weeks, 11 of 13 patients showed improvement in JRA scores, significant decreases in ESR, and significant increase in hemoglobin (Lehman 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Erythema nodosum leprosum, acute cutaneous:</b> Oral: Initial: 100 to 300 mg once daily at bedtime, continue until signs/symptoms subside (usually ~2 weeks), then taper off in 50 mg decrements every 2 to 4 weeks. For severe cases with moderate to severe neuritis, corticosteroids may be initiated with thalidomide (taper off and discontinue corticosteroids when neuritis improves).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients weighing &lt;50 kg: Initiate at lower end of the dosing range</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe cutaneous reaction or patients previously requiring high doses: May be initiated at up to 400 mg once daily at bedtime or in divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Erythema nodosum leprosum, maintenance (prevention/suppression, or with flares during tapering attempts):</b> Oral: Maintain on the minimum dosage necessary to control the reaction; efforts to taper should be repeated every 3 to 6 months, in decrements of 50 mg every 2 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Multiple myeloma:</b> Oral: 200 mg once daily at bedtime (in combination with dexamethasone)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity:</b> Children and Adolescents: ANC &le;750/mm<sup>3</sup>: Withhold treatment if clinically appropriate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">For other observed toxicities, the following have been used in adult patients with multiple myeloma:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Constipation, oversedation: Temporarily withhold or continue with a reduced dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peripheral neuropathy: The manufacturer recommends to temporarily withhold or continue with a reduced dose. The following adjustments have also been recommended (Richardson 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Grade 1: Reduce dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Grade 2: Temporarily interrupt therapy; once resolved to &le; grade 1, resume therapy with a 50% dosage reduction (if clinically appropriate)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Grade 3 or higher: Discontinue therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for renal impairment:</b> Children, Adolescents, and Adults: No adjustment is required for patients with renal impairment and on dialysis (per manufacturer). In a study of six adult patients with end-stage renal disease on dialysis, although clearance was increased by dialysis, a supplemental dose was not needed (Eriksson 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Multiple myeloma:</b> Adult: An evaluation of 29 newly diagnosed adult myeloma patients with renal failure (serum creatinine &ge;2 mg/dL) treated with thalidomide and dexamethasone (some also received cyclophosphamide) found that toxicities and efficacy were similar to patients with normal renal function (Seol 2010). A study evaluating induction therapy with thalidomide and dexamethasone in 31 newly diagnosed adult myeloma patients with renal failure (CrCl &lt;50 mL/minute), including 16 patients with severe renal impairment (CrCl &lt;30 mL/minute) and seven patients on chronic hemodialysis found that toxicities were similar to patients without renal impairment and that thalidomide and dexamethasone could be administered safely (Tosi 2009). The International Myeloma Working Group's (IMWG) recommendations suggest that thalidomide may be safely administered to patients with renal impairment, including those on dialysis (Dimopoulos 2016). The IMWG recommends the use of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (preferred) or the Modification of Diet in Renal Disease (MDRD) formula to evaluate renal function estimation in multiple myeloma patients with a stable serum creatinine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for hepatic impairment:</b> All patients: There are no dosage adjustments provided in manufacturer's labeling (has not been studied); however, thalidomide does not appear to undergo significant hepatic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226457\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Thalomid: 50 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Thalomid: 150 mg, 200 mg [contains fd&amp;c blue #2 (indigotine)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226442\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11234348\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Canada:</b> Access to thalidomide is restricted through a controlled distribution program called RevAid. Only physicians and pharmacists enrolled in this program are authorized to prescribe or dispense thalidomide. Patients must be enrolled in the program by their physicians. Further information is available at www.RevAid.ca or by calling 1-888-738-2431.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10523386\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020785s061lbl.pdf#page=25&amp;token=nm4n0j3BlqRof1TyvuP8MXjNRYLRe+pS/trXMwepL21CYd/ysRseOFNwbFZG9mtI7vwzC7haOUGCqSLcYJ26cLBJndxjnuNUA9ico79fCrfnzVlotxmn285NiPvOBl/H&amp;TOPIC_ID=13090\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020785s061lbl.pdf#page=25</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1038582\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Wear gloves to prevent cutaneous exposure. Do not open or crush capsules. Avoid extensive handling of capsules; capsules should remain in blister pack until ingestion. If exposed to the powder content from broken capsules or body fluids from patients receiving thalidomide, the exposed area should be washed with soap and water. Administer with water, preferably at bedtime, once daily on an empty stomach, at least 1 hour after the evening meal. Doses &gt;400 mg/day may be given in 2 to 3 divided doses. For missed doses, if &lt;12 hours have passed, patient may receive dose; if &gt;12 hours have passed, wait until next dose is due. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132838\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226476\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Protect from light. Keep in original package.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1038545\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of and suppressive maintenance therapy  for cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) (FDA approved in ages &ge;12 years and adults); treatment of newly diagnosed multiple myeloma in combination with dexamethasone (FDA approved in adults). Has also been used for treatment of  Crohn's disease/ulcerative colitis when other therapies have failed, refractory chronic graft-versus-host disease (cGVHD), AIDS-related aphthous stomatitis, systemic juvenile idiopathic arthritis (SJIA), and various malignancies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226506\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Thalidomide may be confused with flutamide, lenalidomide, pomalidomide</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Thalomid may be confused with Revlimid, thiamine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Thalomid [US, Canada] may be confused with Thilomide brand name for lodoxamide [Greece, Turkey]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226505\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Facial edema, peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, drowsiness, headache, malaise, pain, peripheral neuropathy, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Fungal dermatitis, maculopapular rash, nail disease, pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Constipation, nausea, oral candidiasis, toothache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Impotence</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Back pain, neck pain, neck stiffness, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Accidental injury</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute renal failure, amenorrhea, aphthous stomatitis, auditory impairment, biliary obstruction, bradycardia, carpal tunnel syndrome, cerebrovascular accident, change in prothrombin time, chronic myelocytic leukemia, cytomegalovirus disease, diplopia, ECG abnormality, erythema multiforme, erythema nodosum, erythroleukemia, febrile neutropenia, foot-drop, galactorrhea, gastric ulcer, gynecomastia, hangover effect, Hodgkin lymphoma, hypercalcemia, hypersensitivity reaction, hypomagnesemia, hyponatremia, hypothyroidism, increased serum alkaline phosphatase, interstitial pulmonary disease, intestinal perforation, lethargy, loss of consciousness, lymphedema, lymphocytopenia, mental status changes, migraine, myocardial infarction, myxedema, neutropenia, nystagmus, oliguria, orthostatic hypotension, pancytopenia, Parkinson disease, petechia, pleural effusion, pulmonary embolism, pulmonary hypertension, purpura, Raynaud phenomenon, reactivation of HBV, renal failure, seizure, sepsis, septic shock, sexual disorder, sick sinus syndrome, status epilepticus, Stevens-Johnson syndrome, stupor, suicidal tendencies, syncope, thrombocytopenia, tonic-clonic seizures, toxic epidermal necrolysis, tumor lysis syndrome, urinary incontinence, uterine hemorrhage, varicella zoster infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226464\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to thalidomide or any component of the formulation; pregnancy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Hypersensitivity to lenalidomide or pomalidomide; females at risk of becoming pregnant and male patients who are unable to follow or comply with conditions for use (refer to manufacturer labeling); breastfeeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226446\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: May cause leukopenia and neutropenia; avoid initiating therapy if ANC &lt;750/mm<sup>3</sup>. Persistent neutropenia may require treatment interruption. Thrombocytopenia (including grades 3 and 4) has been reported; may require dose reduction, treatment delay, or discontinuation. Monitor for signs and symptoms of bleeding (including petechiae, epistaxis, and GI bleeding), especially if concomitant medication may increase the risk of bleeding. Monitor CBC with differential and platelets. Anemia has also been observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bradycardia: May cause bradycardia; use with caution when administering concomitantly with medications that may also decrease heart rate. May require thalidomide dose reduction or discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause dizziness, drowsiness, and/or somnolence; caution patients about performing tasks which require mental alertness (eg, operating machinery or driving). Avoid ethanol and concomitant medications that may exacerbate these symptoms; dose reductions may be necessary for excessive drowsiness or somnolence.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Constipation: Constipation may commonly occur. May require treatment interruption or dosage reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported (may be fatal); withhold therapy and evaluate if skin rash occurs; permanently discontinue if rash is exfoliative, purpuric, bullous, or if SJS or TEN is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Abnormal liver function tests, hepatitis, and cholestatic jaundice have been reported. Hepatotoxicity (including hepatocellular and cholestatic injury) has been observed rarely (case reports), with a mean time to development of 46 days; most events resolved after discontinuing thalidomide (Vilas-Boas 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity, including erythematous macular rash, possibly associated with fever, tachycardia, and hypotension has been reported. May require treatment interruption for severe reactions; discontinue if recurs with rechallenge.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients who would not tolerate transient hypotensive episodes. When arising from a recumbent position, advise patients to sit upright for a few minutes prior to standing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral neuropathy: Thalidomide is commonly associated with peripheral neuropathy; may be irreversible. Neuropathy generally occurs following chronic use (over months), but may occur with short-term use; onset may be delayed. Use caution with other medications that may also cause peripheral neuropathy. Monitor for signs/symptoms of neuropathy monthly for the first 3 months of therapy and regularly thereafter. Electrophysiological testing may be considered at baseline and every 6 months to detect asymptomatic neuropathy. To limit further damage, immediately discontinue (if clinically appropriate) in patients who develop neuropathy. Reinitiate therapy only if neuropathy returns to baseline; may require dosage reduction or permanent discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancy: Increased incidence of second primary malignancies (SPMs), including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), has been observed in previously untreated multiple myeloma patients receiving thalidomide in combination with melphalan, and prednisone. In addition to AML and MDS, solid tumors have been reported with thalidomide maintenance treatment for multiple myeloma (Usmani 2012). Carefully evaluate patients for SPMs prior to and during treatment and manage as clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Seizures (including grand mal convulsions) have been reported in postmarketing data; monitor closely for clinical changes indicating potential seizure activity in patients with a history of seizures, concurrent therapy with drugs that alter seizure threshold, or conditions that predispose to seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: <b>[US Boxed Warning]: Thalidomide use for the treatment of multiple myeloma is associated with an increased risk for venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE); the risk is increased when used in combination with standard chemotherapy agents, including dexamethasone. In one controlled study, the incidence of VTE was 22.5% in patients receiving thalidomide in combination with dexamethasone, compared to 4.9% for dexamethasone alone. Monitor for signs and symptoms of thromboembolism (shortness of breath, chest pain, or arm or leg swelling) and instruct patients to seek prompt medical attention with development of these symptoms. Consider thromboprophylaxis based on risk factors.</b> Ischemic heart disease, including MI and stroke, also occurred at a higher rate (compared to placebo) in myeloma patients receiving thalidomide plus dexamethasone who had not received prior treatment. Assess individual risk factors for thromboembolism and consider thromboprophylaxis. The American Society of Clinical Oncology guidelines for VTE prophylaxis and treatment recommend thromboprophylaxis for patients receiving thalidomide in combination with chemotherapy and/or dexamethasone; either aspirin or low molecular weight heparin (LMWH) is recommended for lower risk patient and LMWH is recommended for higher-risk patients (Lyman 2013; Lyman 2015). Anticoagulant prophylaxis should be individualized and selected based on the venous thromboembolism risk of the combination treatment regimen, using the safest and easiest to administer (Palumbo 2008). Monitor for signs/symptoms of thromboembolism and advise patients to seek immediate care if symptoms (shortness of breath, chest pain, arm/leg swelling) develop. Other medications that are also associated with thromboembolism should be used with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Patients with a high tumor burden may be at risk for tumor lysis syndrome; monitor closely; institute appropriate management for hyperuricemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Disease-related concerns:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: In a scientific statement from the American Heart Association, thalidomide has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: minor) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple myeloma: An increase in mortality was noted in 2 clinical studies in patients with multiple myeloma who received pembrolizumab in combination with a thalidomide analogue and dexamethasone. Causes of death in the experimental arm (containing pembrolizumab, dexamethasone, and a thalidomide analogue [pomalidomide or lenalidomide]) included myocarditis, SJS, MI, pericardial hemorrhage, cardiac failure, respiratory tract infection, neutropenic sepsis, sepsis, multiple organ dysfunction, respiratory failure, intestinal ischemia, cardiopulmonary arrest, suicide, pulmonary embolism, cardiac arrest, pneumonia, sudden death, and large intestine perforation. Multiple myeloma is not an approved indication for PD-1 or PD-L1 blocking antibodies; pembrolizumab should not be used to treat multiple myeloma in combination with a thalidomide analogue and dexamethasone unless as part of a clinical trial.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Certain adverse reactions (constipation, fatigue, weakness, nausea, hypokalemia, hyperglycemia, DVT, pulmonary embolism, atrial fibrillation) are more likely in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV-infected patients: Thalidomide is associated with increased viral loads in studies conducted prior to the use of antiretroviral therapy. Monitor viral load after the first and third months of therapy, and every 3 months thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warning]: Thalidomide is contraindicated in pregnant women. Thalidomide may cause severe birth defects or embryo-fetal death if taken during pregnancy. Thalidomide cannot be used in women who are pregnant or may become pregnant during therapy as even a single dose may cause severe birth defects. In order to decrease the risk of fetal exposure, thalidomide is available only through a special restricted distribution program (Thalomid REMS). </b>Use is also contraindicated in women who may become pregnant. Pregnancy must be excluded prior to therapy initiation with 2 negative pregnancy tests. Women of reproductive potential must avoid pregnancy beginning 4 weeks prior to therapy, during therapy, during therapy interruptions, and for &ge;4 weeks after therapy is discontinued; two reliable methods of birth control, or abstinence from heterosexual intercourse, must be used. Males taking thalidomide (even those vasectomized) must use a latex or synthetic condom during any sexual contact with women of childbearing potential and for up to 28 days following discontinuation of therapy. Males taking thalidomide must not donate sperm. Some forms of contraception may not be appropriate in certain patients. An intrauterine device (IUD) or implantable contraceptive may increase the risk of infection or bleeding; estrogen containing products may increase the risk of thromboembolism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood donation: Patients should not donate blood during thalidomide treatment and for 4 weeks after therapy discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; REMS program: Due to the embryo-fetal risk, thalidomide is only available through a restricted program under the Thalomid REMS program. Prescribers and pharmacies must be certified with the program to prescribe or dispense thalidomide. Patients must sign an agreement and comply with the REMS program requirements.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300130\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226450\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13090&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Angiogenesis Inhibitors (Systemic) may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the CNS depressant effect of Thalidomide.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexamethasone (Systemic): May enhance the dermatologic adverse effect of Thalidomide. Dexamethasone (Systemic) may enhance the thrombogenic effect of Thalidomide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythropoiesis-Stimulating Agents: May enhance the thrombogenic effect of Thalidomide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May enhance the thrombogenic effect of Thalidomide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): May enhance the thrombogenic effect of Thalidomide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pamidronate: Thalidomide may enhance the nephrotoxic effect of Pamidronate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pembrolizumab: May enhance the adverse/toxic effect of Thalidomide Analogues. Specifically, mortality may be increased when this combination is used for treatment of refractory multiple myeloma.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): May enhance the thrombogenic effect of Thalidomide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vedolizumab: Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zoledronic Acid: Thalidomide may enhance the adverse/toxic effect of Zoledronic Acid. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226466\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">\n      <b>[US Boxed Warning]: Thalidomide is contraindicated in pregnant women. Thalidomide may cause severe birth defects or embryo-fetal death if taken during pregnancy. Thalidomide cannot be used in women who are pregnant or may become pregnant during therapy as even a single dose may cause severe birth defects. In order to decrease the risk of fetal exposure, thalidomide is available only through a special restricted distribution program (Thalomid REMS).</b> Reproduction studies in animals and data from pregnant women have shown evidence of fetal abnormalities; use is contraindicated in women who are or may become pregnant. Anomalies observed in humans include amelia, phocomelia, bone defects, ear and eye abnormalities, facial palsy, congenital heart defects, urinary and genital tract malformations; mortality in ~40% of infants at or shortly after birth has also been reported.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women of reproductive potential must avoid pregnancy beginning 4 weeks prior to therapy, during therapy, during therapy interruptions, and for at least 4 weeks after therapy is discontinued. Two forms of effective/reliable contraception or total abstinence from heterosexual intercourse must be used by females who are not infertile or who have not had a hysterectomy. A negative pregnancy test (sensitivity of at least 50 milliunits/mL) 10 to 14 days prior to therapy, within 24 hours prior to beginning therapy, weekly during the first 4 weeks, and every 4 weeks (every 2 weeks for women with irregular menstrual cycles) thereafter is required for women of childbearing potential. Thalidomide must be immediately discontinued for a missed period, abnormal pregnancy test or abnormal menstrual bleeding; refer patient to a reproductive toxicity specialist if pregnancy occurs during treatment.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Females of reproductive potential (including health care workers and caregivers) must also avoid contact with thalidomide capsules.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Thalidomide is also present in the semen of males. Males (even those vasectomized) must use a latex or synthetic condom during any sexual contact with women of childbearing potential and for up to 28 days following discontinuation of therapy. Males taking thalidomide must not donate sperm.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The parent or legal guardian for patients between 12 to 18 years of age must agree to ensure compliance with the required guidelines.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A pregnancy exposure registry has been created to monitor outcomes in females exposed to thalidomide during pregnancy and female partners of male patients and to understand the root cause for the pregnancy. The pregnancy exposure registry may be contacted at 1-888-423-5436. If pregnancy occurs during treatment, thalidomide must be immediately discontinued and the patient referred to a reproductive toxicity specialist. Any suspected fetal exposure to thalidomide must be reported to the FDA via the MedWatch program (1-800-FDA-1088) and to Celgene Corporation (1-888-423-5436).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1038584\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, platelets; thyroid function tests (TSH at baseline then every 2 to 3 months during thalidomide treatment [Hamnvik 2011]). In HIV-seropositive patients: Viral load after 1 and 3 months, then every 3 months. Pregnancy testing (sensitivity of at least 50 mIU/mL) is required within 24 hours prior to initiation of therapy, weekly during the first 4 weeks, then every 4 weeks in women with regular menstrual cycles or every 2 weeks in women with irregular menstrual cycles. Signs of neuropathy monthly for the first 3 months, then periodically during treatment; consider monitoring of sensory nerve application potential amplitudes (at baseline and every 6 months) to detect asymptomatic neuropathy. Monitor for signs and symptoms of thromboembolism (shortness of breath, chest pain, arm/leg swelling), tumor lysis syndrome, bradycardia, and syncope; monitor for clinical changes indicating potential seizure activity (in patients with a history of seizure).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1038568\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Graft vs host disease: Therapeutic plasma thalidomide levels are 5 to 8 mcg/mL (Vogelsang 1992), although it has been suggested that lower plasma levels (0.5 to 1.5 mcg/mL) may be therapeutic; peak serum thalidomide level after a 200 mg dose: 1.8 mcg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226445\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Thalidomide exhibits immunomodulatory and antiangiogenic characteristics; immunologic effects may vary based on conditions. Thalidomide may suppress excessive tumor necrosis factor-alpha production in patients with erythema nodosum leprosum, yet may increase plasma tumor necrosis factor-alpha levels in HIV-positive patients. In multiple myeloma, thalidomide is associated with an increase in natural killer cells and increased levels of interleukin-2 and interferon gamma. Other proposed mechanisms of action include suppression of angiogenesis, prevention of free-radical-mediated DNA damage, increased cell mediated cytotoxic effects, and altered expression of cellular adhesion molecules.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226463\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Slow, good</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 1.1 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 55% to 66%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Minimal (unchanged drug is the predominant circulating component)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 5.5 to 7.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: ~2 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~92%; &lt;4% of the dose as unchanged drug); feces (&lt;2%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13791503\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;\">A 20 mg/mL oral suspension may be prepared with capsules and a 1:1 mixture of Ora-Sweet and Ora-Plus. Empty the contents of twelve 100 mg capsules into a glass mortar.  Add small portions of the vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to almost 60 mL; transfer to an amber calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label &ldquo;shake well,&rdquo;  &ldquo;protect from light,&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 35 days refrigerated.</p>\n    <div class=\"reference\">Kraft S, Johnson CE, and Tyler RP, &quot;Stability of an Extemporaneously Prepared Thalidomide Suspension,&quot; <i>Am J Health Syst Pharm</i>, 2011, 69(1):56-8.<span class=\"pubmed-id\">22180553</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323954\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Thalomid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (28): $5,742.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (28): $9,320.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (28): $9,966.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (28): $10,612.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226469\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bescamin (PE);</li>\n      <li>Domide (MY);</li>\n      <li>Inmunoprin (CL, CO, EC, PE, UY);</li>\n      <li>Midothal (BD);</li>\n      <li>Myrin (CZ);</li>\n      <li>Talidex (GB, IE);</li>\n      <li>Thado (TW);</li>\n      <li>Thaled (JP);</li>\n      <li>Thalix (IN, PH);</li>\n      <li>Thaloma (KR);</li>\n      <li>Thalomid (AU, BB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bessmertny O and Pham T, &quot;Thalidomide Use in Pediatric Patients,&quot; <i>Ann Pharmacother</i>, 2002, 36(3):521-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/11895068/pubmed\" target=\"_blank\" id=\"11895068\">11895068</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Britton WJ and Lockwood DN, &quot;Leprosy,&quot; <i>Lancet</i>, 2004, 363(9416):1209-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/15081655/pubmed\" target=\"_blank\" id=\"15081655\">15081655</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Browne PV, Weisdorf DJ, DeFor T, et al, &quot;Response to Thalidomide Therapy in Refractory Chronic Graft-Versus-Host Disease,&quot; <i>Bone Marrow Transplant</i>, 2000, 26(8):865-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/11081386/pubmed\" target=\"_blank\" id=\"11081386\">11081386</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group Recommendations for the diagnosis and management of myeloma-related renal impairment. <i>J Clin Oncol</i>. 2016 May;34(13):1544-1557.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/26976420/pubmed\" target=\"_blank\" id=\"26976420\">26976420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ehrenpreis ED, Kane SV, Cohen LB, et al, &quot;Thalidomide Therapy for Patients With Refractory Crohn's Disease: An Open-Label Trial,&quot; <i>Gastroenterology</i>, 1999, 117(6):1271-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/10579967/pubmed\" target=\"_blank\" id=\"10579967\">10579967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eriksson T, H&ouml;glund P, Turesson I, et al, &quot;Pharmacokinetics of Thalidomide in Patients With Impaired Renal Function and While On and Off Dialysis,&quot; <i>J Pharm Pharmacol</i>, 2003, 55(12):1701-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/14738599/pubmed\" target=\"_blank\" id=\"14738599\">14738599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Facchini S, Candusso M, Martelossi S, et al, &quot;Efficacy of Long-Term Treatment With Thalidomide in Children and Young Adults With Crohn Disease: Preliminary Results,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2001, 32(2):178-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/11321389/pubmed\" target=\"_blank\" id=\"11321389\">11321389</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Facon T, Mary JY, Hulin C, et al, &quot;Melphalan and Prednisone Plus Thalidomide Versus Melphalan and Prednisone Alone or Reduced-Intensity Autologous Stem Cell Transplantation in Elderly Patients With Multiple Myeloma (IFM 99-06): A Randomised Trial,&quot; <i>Lancet</i>, 2007, 370(9594):1209-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/17920916/pubmed\" target=\"_blank\" id=\"17920916\">17920916</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. <i>J Natl Cancer Inst</i>. 2011;103(21):1572-1587.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/22010182/pubmed\" target=\"_blank\" id=\"22010182\">22010182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson JM, Greenspan JS, Spritzler J, et al, &ldquo;Thalidomide for the Treatment of Oral Aphthous Ulcers in Patients With Human Immunodeficiency Virus Infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group,&rdquo; <i>N Engl J Med</i>, 1997, 336(21):1487-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/9154767/pubmed\" target=\"_blank\" id=\"9154767\">9154767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kulkarni S, Powles R, Sirohi B, et al, &quot;Thalidomide After Allogeneic Haematopoietic Stem Cell Transplantation: Activity in Chronic But Not in Acute Graft-Versus-Host Disease,&quot; <i>Bone Marrow Transplant</i>, 2003, 32(2):165-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/12838281/pubmed\" target=\"_blank\" id=\"12838281\">12838281</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lazzerini M, Martelossi S, Marchetti F, et al, &quot;Efficacy and Safety of Thalidomide in Children and Young Adults With Intractable Inflammatory Bowel Disease: Long-Term Results,&quot; <i>Aliment Pharmacol Ther</i>, 2007, 25(4):419-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/17269997/pubmed\" target=\"_blank\" id=\"17269997\">17269997</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehman TJ, Schechter SJ, Sundel RP, et al, &quot;Thalidomide for Severe Systemic Onset Juvenile Rheumatoid Arthritis: A Multicenter Study,&quot; <i>J Pediatr</i>, 2004, 145(6):856-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/15580219/pubmed\" target=\"_blank\" id=\"15580219\">15580219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martelossi S, Marchetti F, Lenhard A, et al, &quot;Treatment With Thalidomide in Children and Adolescents With Inflammatory Bowel Disease,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2004, 39(1):S282-3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matthews SJ and McCoy C, &quot;Thalidomide: A Review of Approved and Investigational Uses,&quot; <i>Clin Ther</i>, 2003, 25(2):342-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/12749503/pubmed\" target=\"_blank\" id=\"12749503\">12749503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mehta P, Kedar A, Graham-Pole J, et al, &quot;Thalidomide in Children Undergoing Bone Marrow Transplantation: Series at a Single Institution and Review of the Literature,&quot; <i>Pediatrics</i>, 1999, 103(4):e44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/10103336/pubmed\" target=\"_blank\" id=\"10103336\">10103336</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Okafor MC, &quot;Thalidomide for Erythema Nodosum Leprosum and Other Applications,&quot; <i>Pharmacotherapy</i>, 2003, 23(4):481-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/12680478/pubmed\" target=\"_blank\" id=\"12680478\">12680478</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palumbo A, Rajkumar SV, Dimopoulos MA, et al, &quot;Prevention of Thalidomide- and Lenalidomide-Associated Thrombosis in Myeloma,&quot; <i>Leukemia</i>, 2008, 22(2):414-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/18094721/pubmed\" target=\"_blank\" id=\"18094721\">18094721</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker PM, Chao N, Nademanee A, et al, &quot;Thalidomide as Salvage Therapy for Chronic Graft-Versus-Host Disease,&quot; <i>Blood</i>, 1995, 86(9):3604-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/7579470/pubmed\" target=\"_blank\" id=\"7579470\">7579470</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Priolo T, Lamba LD, Giribaldi G, et al, &quot;Childhood Thalidomide Neuropathy: A Clinical and Neurophysiologic Study,&quot; <i>Pediatr Neurol</i>, 2008, 38(3):196-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/18279755/pubmed\" target=\"_blank\" id=\"18279755\">18279755</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. <i>Leukemia</i>. 2012;26(4):595-608.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/22193964/pubmed\" target=\"_blank\" id=\"22193964\">22193964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rovelli A, Arrigo C, Nesi F, et al, &quot;The Role of Thalidomide in the Treatment of Refractory Chronic Graft-Versus-Host Disease Following Bone Marrow Transplantation in Children,&quot; <i>Bone Marrow Transplant</i>, 1998, 21(6):577-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/9543061/pubmed\" target=\"_blank\" id=\"9543061\">9543061</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seol Y, Chung J, Kwon B, et al, &ldquo;Treatment for Patients With Multiple Myeloma Complicated by Renal Failure by Thalidomide-Based Regimens,&rdquo; <i>J Clin Oncol</i>, 2010, 28(Suppl):e13093 [Abstract e13093 From 2010 ASCO Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teo SK, Colburn WA, Tracewell WG, et al, &quot;Clinical Pharmacokinetics of Thalidomide,&quot; <i>Clin Pharmacokinet</i>, 2004, 43(5):311-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/15080764 /pubmed\" target=\"_blank\" id=\"15080764 \">15080764 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thalomid (thalidomide) [prescribing information]. Summiy NJ: Celegene Corporation; February 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thompson JL and Hansen LA, &quot;Thalidomide Dosing in Patients With Relapsed or Refractory Multiple Myeloma,&quot; <i>Ann Pharmacother</i>, 2003, 37(4):571-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/12659617/pubmed\" target=\"_blank\" id=\"12659617\">12659617</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tosi P, Zamagni E, Tacchetti P, et al, &ldquo;Thalidomide-Dexamethasone as Induction Therapy Prior to Autologous Stem-Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma and Renal Failure,&rdquo; <i>Blood</i>, 2009, 114(22):4934 [Abstract 4934 From 2009 ASH Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Usmani S, Sexton R, Hoering A, et al. Second malignancies in total therapy 2 and 3 trials for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. <i>Blood</i>. 2012;120(8):1597-1600.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/22674807/pubmed\" target=\"_blank\" id=\"22674807\">22674807</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al, &quot;An Open-Label Pilot Study of Low-Dose Thalidomide in Chronically Active, Steroid-Dependent Crohn's Disease,&quot; <i>Gastroenterology</i>, 1999, 117(6):1278-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/10579968/pubmed\" target=\"_blank\" id=\"10579968\">10579968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vogelsang GB, Farmer ER, Hess AD, et al, &quot;Thalidomide for the Treatment of Chronic Graft-Versus-Host Disease,&quot; <i>N Engl J Med</i>, 1992, 326(16):1055-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/1549151/pubmed\" target=\"_blank\" id=\"1549151\">1549151</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wolff D, Schleuning M, von Harsdorf S, et al, &quot;Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-Versus-Host Disease,&quot; <i>Biol Blood Marrow Transplant</i>, 2011, 17(1):1-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/20685255/pubmed\" target=\"_blank\" id=\"20685255\">20685255</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zheng CF, Xu JH, Huang Y, et al, &quot;Treatment of Pediatric Refractory Crohn's Disease With Thalidomide,&quot; <i>World J Gastroenterol</i>, 2011, 17(10):1286-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thalidomide-pediatric-drug-information/abstract-text/21455327/pubmed\" target=\"_blank\" id=\"21455327\">21455327</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13090 Version 144.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708930\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F226481\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F226482\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1038544\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1038576\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F226457\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F226442\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11234348\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F10523386\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1038582\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132838\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F226476\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1038545\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F226506\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F226505\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F226464\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F226446\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300130\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F226450\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F226466\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1038584\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1038568\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F226445\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F226463\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F13791503\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323954\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F226469\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13090|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">Thalidomide: Drug information</a></li><li><a href=\"topic.htm?path=thalidomide-patient-drug-information\" class=\"drug drug_patient\">Thalidomide: Patient drug information</a></li></ul></div></div>","javascript":null}